Cargando…

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine

BACKGROUND: Many children and adolescents with attention deficit/hyperactivity disorder (ADHD) are treated with stimulant and non-stimulant medication. ADHD medication may be associated with cardiovascular effects. It is important to identify whether mean group effects translate into clinically rele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hennissen, Leonie, Bakker, Mireille J., Banaschewski, Tobias, Carucci, Sara, Coghill, David, Danckaerts, Marina, Dittmann, Ralf W., Hollis, Chris, Kovshoff, Hanna, McCarthy, Suzanne, Nagy, Peter, Sonuga-Barke, Edmund, Wong, Ian C. K., Zuddas, Alessandro, Rosenthal, Eric, Buitelaar, Jan K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336546/ https://www.ncbi.nlm.nih.gov/pubmed/28236285 http://dx.doi.org/10.1007/s40263-017-0410-7

Ejemplares similares

Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study
por: Inglis, S K, et al.
Publicado: (2016)

Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale
por: Kovshoff, Hanna, et al.
Publicado: (2016)

Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)
por: McCarthy, Suzanne, et al.
Publicado: (2018)

European guidelines on managing adverse effects of medication for ADHD
por: Graham, J., et al.
Publicado: (2010)

Erratum to: Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations
por: Sergeant, Joseph A., et al.
Publicado: (2010)

The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG)
por: Coghill, David, et al.
Publicado: (2021)

ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group
por: Cortese, Samuele, et al.
Publicado: (2020)

The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
por: Danckaerts, Marina, et al.
Publicado: (2009)

Eunethydis: a statement of the ethical principles governing the relationship between the European group for ADHD guidelines, and its members, with commercial for-profit organisations
por: Sergeant, Joseph A., et al.
Publicado: (2010)

An inventory of European data sources for the long-term safety evaluation of methylphenidate
por: Murray, Macey L., et al.
Publicado: (2013)

Characterization of Amphetamine, Methylphenidate, Nicotine, and Atomoxetine on Measures of Attention, Impulsive Action, and Motivation in the Rat: Implications for Translational Research
por: Higgins, Guy A., et al.
Publicado: (2020)

Remote assessment of ADHD in children and adolescents: recommendations from the European ADHD Guidelines Group following the clinical experience during the COVID-19 pandemic
por: Santosh, P., et al.
Publicado: (2023)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
por: Wei, Wei, et al.
Publicado: (2023)

Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
por: Coghill, David, et al.
Publicado: (2013)

Atomoxetine/Methylphenidate Effects on Social Play Behavior
por: Millichap, J. Gordon
Publicado: (2015)

Shared and Drug-Specific Effects of Atomoxetine and Methylphenidate on Inhibitory Brain Dysfunction in Medication-Naive ADHD Boys
por: Cubillo, Ana, et al.
Publicado: (2014)

Single-dose effects of methylphenidate and atomoxetine on functional connectivity during an n-back task in boys with ADHD
por: Kowalczyk, Olivia S., et al.
Publicado: (2023)

Erratum to: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
por: Coghill, David, et al.
Publicado: (2015)

Amphetamines, Atomoxetine and the Risk of Serious Cardiovascular Events in Adults
por: Schelleman, Hedi, et al.
Publicado: (2013)

Amphetamine Positive Urine Toxicology Screen Secondary to Atomoxetine
por: Fenderson, Joshua L., et al.
Publicado: (2013)

Experimental Investigations on Dopamine Transmission Can Provide Clues on the Mechanism of the Therapeutic Effect of Amphetamine and Methylphenidate in ADHD
por: Carboni, Ezio, et al.
Publicado: (2004)

The limits of motivational influence in ADHD: no evidence for an altered reaction to negative reinforcement
por: Van Dessel, Jeroen, et al.
Publicado: (2021)

Different effects of methylphenidate and atomoxetine on the behavior and brain transcriptome of zebrafish
por: Suzuki, Shiho, et al.
Publicado: (2020)

Transition from Methylphenidate to Atomoxetine: reasons for switching and clinical outcome
por: Cassar, Fabrizia, et al.
Publicado: (2021)

Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries
por: Nafees, Beenish, et al.
Publicado: (2014)

Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy
por: Bro, Søren Pauli, et al.
Publicado: (2015)

Methylphenidate-induced Exacerbation of Chorea in a Child Resolved with Switching to Atomoxetine
por: Ekinci, Ozalp, et al.
Publicado: (2020)

Comorbidities in ADHD children treated with methylphenidate: a database study
por: Kraut, Angela A, et al.
Publicado: (2013)

A critical appraisal of atomoxetine in the management of ADHD
por: Childress, Ann C
Publicado: (2015)

Factors Associated With Initiation With Atomoxetine Versus Stimulants in the Treatment of Adults With ADHD: Retrospective Analysis of Administrative Claims Data
por: Van Brunt, David L., et al.
Publicado: (2006)

Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians
por: Dittmann, Ralf W, et al.
Publicado: (2009)

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: Preliminary indications from a secondary analysis of the COMACS study data
por: Sonuga-Barke, Edmund JS, et al.
Publicado: (2004)

Methylphenidate significantly improves declarative memory functioning of adults with ADHD
por: Verster, Joris C., et al.
Publicado: (2010)

Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review
por: Quintero, Javier, et al.
Publicado: (2022)

Atomoxetine: a novel treatment for child and adult ADHD
por: Ledbetter, Marcialee
Publicado: (2006)

Atomoxetine for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children with ADHD and dyslexia
por: Sumner, Calvin R, et al.
Publicado: (2009)

ADHD, Methylphenidate, and Childhood Epilepsy
por: Sharma, Rahul, et al.
Publicado: (2016)

The impact of ADHD on the health and well-being of ADHD children and their siblings
por: Peasgood, Tessa, et al.
Publicado: (2016)

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?
por: Fairman, Kathleen A., et al.
Publicado: (2018)

DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics
por: Turic, Darko, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_t2vn34el6ta3u8n2b95b0kttom